- Home
- IMAB vs MRVI Comparison
IMAB vs MRVI Comparison
Compare IMAB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- MRVI
- Stock Information
- Founded
- IMAB 2014
- MRVI 2014
- Country
- IMAB United States
- MRVI United States
- Employees
- IMAB N/A
- MRVI N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- MRVI Health Care
- Exchange
- IMAB Nasdaq
- MRVI Nasdaq
- Market Cap
- IMAB 394.2M
- MRVI 376.2M
- IPO Year
- IMAB 2020
- MRVI 2020
- Fundamental
- Price
- IMAB $4.39
- MRVI $3.34
- Analyst Decision
- IMAB Strong Buy
- MRVI Hold
- Analyst Count
- IMAB 6
- MRVI 9
- Target Price
- IMAB $7.17
- MRVI $4.54
- AVG Volume (30 Days)
- IMAB 1.7M
- MRVI 1.4M
- Earning Date
- IMAB 11-02-2025
- MRVI 11-06-2025
- Dividend Yield
- IMAB N/A
- MRVI N/A
- EPS Growth
- IMAB N/A
- MRVI N/A
- EPS
- IMAB N/A
- MRVI N/A
- Revenue
- IMAB N/A
- MRVI $219,830,000.00
- Revenue This Year
- IMAB N/A
- MRVI N/A
- Revenue Next Year
- IMAB N/A
- MRVI $7.23
- P/E Ratio
- IMAB N/A
- MRVI N/A
- Revenue Growth
- IMAB N/A
- MRVI N/A
- 52 Week Low
- IMAB $0.60
- MRVI $1.67
- 52 Week High
- IMAB $5.90
- MRVI $8.54
- Technical
- Relative Strength Index (RSI)
- IMAB 59.97
- MRVI 69.44
- Support Level
- IMAB $3.98
- MRVI $2.94
- Resistance Level
- IMAB $4.51
- MRVI $3.30
- Average True Range (ATR)
- IMAB 0.30
- MRVI 0.20
- MACD
- IMAB 0.07
- MRVI 0.04
- Stochastic Oscillator
- IMAB 89.30
- MRVI 91.98
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.